Amarin Corp Plcuk (AMRN) EPS (Diluted) Growth (3y) (2013 - 2026)
Amarin Corp Plcuk (AMRN) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.00% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -59.00% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 11.31% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.35% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -130.36% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -28.10% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -34.20% |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 24.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104.35% |
| Mar 31, 2026 | -131.34% |
| Dec 31, 2025 | -209.49% |
| Sep 30, 2025 | -208.35% |
| Jun 30, 2025 | -57.18% |
| Mar 31, 2025 | -112.32% |
| Dec 31, 2024 | -73.69% |
| Sep 30, 2024 | -22.62% |
| Jun 30, 2024 | -42.47% |
| Mar 31, 2024 | -390.20% |
| Dec 31, 2023 | -45.79% |
| Sep 30, 2023 | -39.50% |
| Jun 30, 2023 | -80.67% |
| Mar 31, 2023 | 10.70% |
| Dec 31, 2022 | -53.06% |
| Sep 30, 2022 | -8.80% |
| Jun 30, 2022 | -217.28% |
| Mar 31, 2022 | -2.20% |
| Dec 31, 2021 | 32.43% |
| Sep 30, 2021 | 26.29% |